Targeted Nanoradiopharmaceuticals as a Molecular Approach for Theranostic Applications
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (31 March 2025) | Viewed by 1289
Special Issue Editors
Interests: radiopharmaceutical sciences; targeted radiotherapy; theranostics; molecular imaging; combined therapies; nanoradiopharmaceuticals; radiolabeled nanoparticles
Interests: drug delivery; nanoparticles; therapy; imaging; theranostics; radiolabeled nanoparticles
Interests: radiopharmaceutical chemistry; targeted radionuclide therapy; molecular imaging; PET and SPECT preclinical imaging; radiopharmacokinetics; endoradiotherapy; dosimetric studies
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The field of nanoparticle-based radiopharmaceuticals holds great promise for the diagnosis and treatment of cancer and other diseases. Nanoparticles can be used to deliver radionuclides, cytotoxic drugs, or imaging agents, offering multimodal platforms as integral approaches in the field of nuclear medicine. This Special Issue aims to explore strategies to improve targeting efficiency and to develop methods for encapsulating components that ensure safety and efficacy, in order to propose new approaches for the clinical translation phase.
The sub-topics to be covered within this Special Issue are as follows:
- Radiopharmaceuticals based on organic nanoparticles for combined therapies;
- Radiopharmaceuticals based on metallic nanoparticles for theranostic purposes;
- Radiolabeled nanoparticles for diagnosis or therapy.
Dr. Blanca Ocampo García
Dr. Enrique Morales-Avila
Dr. Laura Melendez-Alafort
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug delivery
- nanoparticles
- therapy
- imaging
- theranostics
- radiolabeled nanoparticles
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
